{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T17:38:04Z","timestamp":1795196284429,"version":"4.10.3"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ebm-journal.org"],"crossmark-restriction":true},"short-container-title":["Exp. Biol. Med."],"abstract":"<jats:p>Inflammatory breast cancer (IBC) is a rare and aggressive breast cancer subtype with poor survival. Identifying novel biomarkers is needed to predict survival for this highly progressive form of breast cancer. In this retrospective study, we investigated pan-immune-inflammation value (PIV), a novel immune-inflammation-based biomarker which combined the peripheral blood parameters (lymphocytes, monocytes, neutrophils, and platelets) in a retrospective cohort of 143 IBC patients. Then we explored the difference of PIV levels in IBC and non-IBC cohorts and the relationship between PIV and clinical characteristics in IBC patients. The survival rates of disease-free survival (DFS) and overall survival (OS) in IBC patients were analyzed and univariate and multivariate statistics were used to evaluate the prognostic value. PIV had the most significantly predictive value in IBC patients compared with other peripheral blood parameters. The mean PIV value in IBC patients was significantly higher than non-IBC patients, and the significant difference between the IBC and non-IBC was also observed in subgroups with different clinical stages and pathologic types. Furthermore, PIV performed an extensive systemic immune prognostic factor on both DFS and OS in IBC patients, and PIV was identified an independent prognostic indicator for survival outcome in IBC patients in univariate and multivariate models. Our retrospective study demonstrated the prognostic value of PIV in IBC patients, suggesting the potential application of PIV in IBC treatment outcomes. PIV would also provide some insights into the mechanisms underlying the role of immune and inflammation in IBC development and progression.<\/jats:p>","DOI":"10.3389\/ebm.2025.10493","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T05:10:09Z","timestamp":1746076209000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Pan-immune-inflammation value predicts survival in inflammatory breast cancer patients"],"prefix":"10.3389","volume":"250","author":[{"given":"Yingjia","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiankang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingjian","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3892\/mco.2018.1773","article-title":"Inflammatory breast cancer in 210 patients: a retrospective study on epidemiological, anatomo-clinical features and therapeutic results","volume":"10","author":"Manai","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.critrevonc.2014.09.003","article-title":"Inflammatory breast cancer: an overview","volume":"93","author":"van Uden","year":"2015","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.ajog.2021.04.217","article-title":"Inflammatory breast cancer: early recognition and diagnosis is critical","volume":"225","author":"Hester","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/annonc\/mdq345","article-title":"International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment","volume":"22","author":"Dawood","year":"2011","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/jnci\/dji172","article-title":"Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute","volume":"97","author":"Hance","year":"2005","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"B6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41568-018-0010-y","article-title":"Inflammatory breast cancer biology: the tumour microenvironment is key","volume":"18","author":"Lim","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13058-020-01371-x","article-title":"Immune phenotype of patients with stage IV metastatic inflammatory breast cancer","volume":"22","author":"Fernandez","year":"2020","journal-title":"Breast Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.7150\/jca.17595","article-title":"The tumor microenvironment and inflammatory breast cancer","volume":"8","author":"Huang","year":"2017","journal-title":"J Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccr.2014.03.021","article-title":"A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis","volume":"25","author":"Su","year":"2014","journal-title":"Cancer Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"S449","DOI":"10.21037\/tcr.2019.03.24","article-title":"Pathological and molecular characteristics of inflammatory breast cancer","volume":"8","author":"Di Bonito","year":"2019","journal-title":"Transl Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.breast.2020.08.006","article-title":"A high neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with a worse outcome in inflammatory breast cancer","volume":"53","author":"Van Berckelaer","year":"2020","journal-title":"The Breast"},{"key":"B13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10549-023-06979-z","article-title":"Monocyte-to-lymphocyte ratio as predictor of cancer therapy-related cardiotoxicity in patients with breast cancer: a pilot cohort study","volume":"200","author":"Pivatto J\u00fanior","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"B14","doi-asserted-by":"publisher","first-page":"E36315","DOI":"10.1097\/md.0000000000036315","article-title":"Peripheral blood inflammatory indexes in breast cancer: a review","volume":"102","author":"Xie","year":"2023","journal-title":"Medicine"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1223786","DOI":"10.3389\/FONC.2023.1223786","article-title":"Clinical utility of the pan-immune-inflammation value in breast cancer patients","volume":"13","author":"Qi","year":"2023","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41416-020-0894-7","article-title":"The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials","volume":"123","author":"Fuc\u00e0","year":"2020","journal-title":"Br J Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"830138","DOI":"10.3389\/FONC.2022.830138","article-title":"Pan-immune-inflammation value: a new prognostic index in operative breast cancer","volume":"12","author":"Lin","year":"2022","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3390\/ph17070824","article-title":"Prognostic significance of pan-immune-inflammation value in patients with HER2-positive metastatic breast cancer treated with trastuzumab emtansine","volume":"17","author":"Sahin","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1007\/s00432-022-03929-y","article-title":"Pan-immune-inflammation value independently predicts disease recurrence in patients with Merkel cell carcinoma","volume":"148","author":"Gambichler","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2217\/imt-2024-0031","article-title":"Prognostic value of peripheral blood neutrophil\/lymphocyte ratio, platelet\/lymphocyte ratio, pan-immune-inflammation value and systemic immune-inflammation index for the efficacy of immunotherapy in patients with advanced gastric cancer","volume":"16","author":"Fu","year":"2024","journal-title":"Immunotherapy"},{"key":"B21","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.2147\/jir.s385328","article-title":"Low pre-ChemoradiotherapyPan-immune-inflammation value (PIV) measures predict better survival outcomes in locally advanced pancreatic adenocarcinomas","volume":"15","author":"Topkan","year":"2022","journal-title":"J Inflamm Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"17588359231165978","DOI":"10.1177\/17588359231165978","article-title":"The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis","volume":"15","author":"Provenzano","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s10549-020-05785-1","article-title":"Obesity and related conditions and risk of inflammatory breast cancer: a nested case\u2013control study","volume":"183","author":"Schairer","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1016\/s1470-2045(17)30192-4","article-title":"Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system","volume":"18","author":"Fouad","year":"2017","journal-title":"The Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.7150\/jca.25691","article-title":"Prognostic value of Systemic immune-inflammation index in cancer: a meta-analysis","volume":"9","author":"Yang","year":"2018","journal-title":"J Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"882896","DOI":"10.3389\/fonc.2022.882896","article-title":"Circulating inflammatory cells in patients with metastatic breast cancer: implications for treatment","volume":"12","author":"Gianni","year":"2022","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1929724","DOI":"10.1080\/2162402X.2021.1929724","article-title":"Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors","volume":"10","author":"Bertucci","year":"2021","journal-title":"Oncoimmunology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.7150\/jca.13098","article-title":"Circulating tumor cells (CTC) are associated with defects in adaptive immunity in patients with inflammatory breast cancer","volume":"7","author":"Mego","year":"2016","journal-title":"J Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3390\/CELLS9040855","article-title":"Platelet-leukocyte interplay in cancer development and progression","volume":"9","author":"Stoiber","year":"2020","journal-title":"Cells"},{"key":"B31","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.celrep.2014.12.039","article-title":"Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer","volume":"10","author":"Sagiv","year":"2015","journal-title":"Cell Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.3390\/cancers14112675","article-title":"The association between the Pan\u2010Immune\u2010Inflammation value and cancer prognosis: a systematic review and meta\u2010analysis","volume":"14","author":"Guven","year":"2022","journal-title":"Cancers"},{"key":"B33","doi-asserted-by":"publisher","first-page":"14662","DOI":"10.1038\/s41598-021-94184-7","article-title":"Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy","volume":"11","author":"\u015eahin","year":"2021","journal-title":"Sci Rep"}],"container-title":["Experimental Biology and Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.ebm-journal.org\/articles\/10.3389\/ebm.2025.10493\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T05:10:09Z","timestamp":1746076209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ebm-journal.org\/articles\/10.3389\/ebm.2025.10493\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":33,"alternative-id":["10.3389\/ebm.2025.10493"],"URL":"https:\/\/doi.org\/10.3389\/ebm.2025.10493","relation":{},"ISSN":["1535-3699"],"issn-type":[{"value":"1535-3699","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]},"article-number":"10493"}}